Canopy Growth's revenue and EBITDA have been disappointing, and analysts' projections for FY25 and FY26 remain weak. Read why ...

Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. For the current quarter, Canopy Growth is expected ...

It has experienced a hiccup, but the company is still on the right path. That’s the opinion of Roth MKM analyst Bill Kirk on ...

In a report released on November 8, Lisa Lewandowski from Bank of America Securities reiterated a Sell rating on Canopy Growth (CGC – Research Report), with a price target of C$ ... dampen investor ...

Analysts estimate that Canopy Growth will report an earnings per share (EPS) of $-0.32. The announcement from Canopy Growth is eagerly anticipated, with investors seeking news of surpassing estimates ...

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Aurora's international medical cannabis business bolstered its results, with European sales doubling quarter-over-quarter.

My name is Nicole, and I will be your conference operator today. I would like to welcome you to Canopy Growth's second ...

Let's dive into two cannabis giants, and which one may be the better pick for long-term investors. The post Should You Buy ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...